BiClamp® forcep liver transection versus clamp crushing technique for liver resection: study protocol for a randomized controlled trial by unknown
TRIALS
Chen et al. Trials  (2015) 16:201 
DOI 10.1186/s13063-015-0722-1STUDY PROTOCOL Open AccessBiClamp® forcep liver transection versus clamp
crushing technique for liver resection: study
protocol for a randomized controlled trial
Jiang-ming Chen1†, Wei Geng2†, Fu-bao Liu3, Hong-chuan Zhao3, Sheng-xue Xie1, Hui Hou1, Yi-jun Zhao3,
Guo-bin Wang3 and Xiao-ping Geng1*Abstract
Background: Blood loss and the requirement of blood transfusions during liver transection have been shown to
correlate well with higher morbidity and mortality rates and a worse prognosis. Various devices for liver parenchymal
transection have been developed to reduce intraoperative blood loss. The goal of this study is to evaluate the safety
and effectiveness of BiClamp® forcep transection compared to a clamp crushing technique in patients undergoing
liver resection.
Methods/Design: This study will include patients 18 years and older scheduled for hepatectomy with hepatic vascular
exclusion who give informed consent. A sample size of 48 patients in each randomization arm will be calculated to
detect a difference in the reduction of blood loss of approximately 200 ml (90% power and α = 0.05 (two-tailed)). The
primary efficacy endpoint of the trial will be the total intraoperative blood loss based on the randomized dissection
technique. The statistical analysis is based on the intention-to-treat population. Patients will be followed up on for three
months for complications and adverse events.
Discussion: This prospective, single-center, randomized controlled, single-blinded, two-group parallel trial is designed
to assess the efficacy and safety of BiClamp forcep hepatectomy versus clamp crushing for parenchymal transection
during elective hepatic resection.
Trial registration: This trial was registered with Clinicaltrials.gov (identifier: NCT02197481) on 15 July 2014.
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Minimization of blood loss during liver resection re-
mains a major concern for hepatic surgeons due to the
correlations among excessive hemorrhage, requirement
of blood transfusions, higher morbidity and mortality
rates and poor long-term outcomes [1-3]. In the last few
decades, various techniques have been adopted to de-
crease intraoperative blood loss during hepatectomy,
including inflow occlusion and low central venous pres-
sures. Assuming that inflow occlusion and low central ven-
ous pressure (CVP) anesthesia cause significant damage via* Correspondence: xp_geng@163.net
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unless otherwise stated.ischemia and reperfusion [4,5], the method applied for
hepatectomy has been considered to be the most critical
factor influencing intraoperative blood loss [6].
Since the clamp crushing technique was introduced in
the 1980s [7], numerous high-tech equipment has been
developed to improve parenchymal transection [8-10].
Randomized clinical trials and a recent meta-analysis
have shown that these modern devices result in similar
blood loss and transfusion requirements compared to
the clamp crushing technique, but with a higher cost
due cost of the device and disposable medical apparatus
[6,8-10]. The optimal method for liver parenchymal div-
ision to obtain minimal blood loss is controversial.
Therefore, hepatic surgeons still select the method for
liver transection according to their own preferences.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tromedizin, Tübingen, Germany) is a novel hemostatic
device that can seal large tissue bundles and blood
vessels up to 7 mm in diameter. The BiClamp forceps
resist repetitive autoclaving sterilization, which re-
duces health care costs and medical waste. In a ran-
domized clinical trial, the application of BiClamp
forceps significantly decreased operation time, blood
loss and costs in patients undergoing mastectomy and
vaginal hysterectomy [11,12]. Our retrospective ana-
lysis has provided primary evidence for BiClamp for-
cep efficacy and safety for liver transection [13].
However, the retrospective non-randomized design of
this study could not draw a definitive conclusion.
Therefore, we conduct this randomized controlled




The objective of this trial is to compare two different
liver transection techniques for liver resection in regards
to the total intraoperative blood loss, operation time,
liver transection time, intraoperative blood transfusion
requirement, reoperation, hepatic injury, duration of
postoperative hospital stay, total hospitalization expendi-
tures, mortality and morbidity.
Patient involvement
The sample size is based on a two-sided t-test for differ-
ences with respect to the primary parameter and pri-
mary analysis. In a retrospective analysis of our own
series, the mean intraoperative blood loss was 450 ml
those who underwent BiClamp forceps liver resection,
with a standard deviation of 350 ml [14,15]. With a two-
sided level of significance α = 5% and a power of 1-β =
90%, a sample size of 43 patients in each group is re-
quired to detect a difference in the reduction of blood
loss of approximately 200 ml (NCSS and PASS 11
(NCSS, Utah, USA). Assuming an expected withdrawal
rate of 10% during the trial, 10 additional patients will
be randomized, and a total number of 96 patients need
to be enrolled (Figure 1).
Eligibility criteria
Inclusion criteria
Patients who meet the following criteria will be included
in the study:
1. Above 18 years of age,
2. Elective hepatic resection due to benign or
malignant hepatobiliary disease,
3. Child-Pugh class A or B liver function and
4. Informed consent.Exclusion criteria
Patients who meet any of the following criteria will be
excluded from the study:
1. Participation in concurrent intervention trials with
interference in the outcome of this study,
2. Laparoscopic hepatectomy,
3. Preoperative liver function evaluation: Child-Pugh
class C,
4. Lack of compliance or
5. Pregnancy or lactation.
Withdrawal
Patients can withdraw at their own request or at the
legal representative’s request at any time during the trial.
Patients may also be withdrawn if, in the investigator’s
opinion, continuation of the trial may be detrimental to
the patient’s wellbeing. The reason for all withdrawals
will be recorded in the clinical report forms (CRFs) and
in the patient’s medical records. All data will be analyzed
according to the intention-to-treat (ITT) principle [16].
Ethics, study registration and consent
The final protocol was approved by the Ethics Commit-
tee of the Second Affiliated Hospital of Anhui Medical
University (approval number: KY201406). The trial
protocol was registered with the Clinicaltrials.gov proto-
col registration system (identifier: NCT02197481). All
patients who are scheduled for liver resection at the De-
partment of General Surgery, The Second Affiliated
Hospital of Anhui Medical University and The First Af-
filiated Hospital of Anhui Medical University will be
screened for eligibility and written informed consent.
The study procedure, benefits, risks and data manage-
ment will be clarified in detail during the preoperative
conversation.
Trial interventions
Group A: clamp crushing technique
In the clamp crushing technique group, the parenchy-
mal transection is crushed using Kelly clamps (Geister,
Badenia-Wirtembergia, Germany), progressive hemostasis
of the vessels with titanium clips (Johnson&Johnson,
Chihuahua, Mexico) or ligations, and coagulation by argon
beam or electrocauterization ( ERBE Elektromedizin,
Tübingen, Germany). Small vessels (≤1 mm) and minor
oozing are controlled with bipolar electrocautery ( ERBE
Elektromedizin, Tübingen, Germany). All other structures,
including major intrahepatic bile ducts, are ligated or
sutured.
Group B: BiClamp forceps hepatectomy
The power of the BiClamp forceps (Figure 2) is set to
level four. The underlying liver tissue is divided, and the
Figure 2 BiClamp forceps liver transection. A BiClamp forceps; B The surgical process of hepatectomy by BiClamp forceps.
Figure 1 Flowchart according to CONSORT (Figure 1).
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forceps. The Glissonian sheaths or hepatic veins with a
diameter larger than 3 mm are ligated and divided in the
conventional manner to reduce postoperative bile leak-
age and intraoperative blood loss.
Primary and secondary endpoints
Primary endpoint
The primary efficacy endpoint of the trial will be the total
intraoperative blood loss using the randomized dissection
technique, which is defined as blood loss from the begin-
ning of the surgical procedure (skin incision) to the end of
the surgical procedure (closure of the skin). The amount of
blood loss is estimated by including the amount of blood
collected in the suction containers, weighing the soaked
swabs after subtracting the rinse fluids and ascites, and
weighing the dry swabs that were used during operation
(assuming that 1 ml of blood is equal to 1 g).
Secondary endpoints
Secondary outcomes will be operation time; liver transec-
tion time; transection speed; total blood loss per unit tran-
section area; incidence and amount of intraoperative blood
transfusion, reoperation and hepatic injury; duration of
postoperative hospital stay; mortality; total hospitalizationTable 1 Definition of secondary endpoints
Secondary endpoint Definition and assessment of outcomes
Operation time Time from incision to end of skin closure (m
Liver transection time Time from beginning to end of liver resect
Liver transection area Area estimated using Adobe Photoshop 7.0
shape of the transection plane, which was
Liver transection speed Speed calculated as the transection area di
Total blood loss per unit
transection area
Blood loss calculated as the total blood los
Intraoperative blood transfusion The indications for blood transfusion were m
within stable hemodynamic measures.
Postoperative hospital stay Time from day of operation until discharge
Total hospitalization
expenditure
Costs from admission to discharge ($)
Postoperative liver injury Serum levels of the aspartate aminotransfe
normalized ratio on postoperative days one
Mortality Death due to any cause until 90 days after
Morbidity Postoperative complications will be recorde
graded according to the Clavien-Dindo cla
Biliary leakage: the international study grou
Post-hepatectomy liver failure: ISGPS defini
Post-hepatectomy hemorrhage: ISGPS defin
Intra-abdominal fluid collection or abscess: an
with abdominal discomfort or pain, or elevati
Pneumonia: infection of the lung with evid
and/or leukocytes >100,000/ml) not caused
on a chest X-ray, requiring antibiotic therapexpenditure; and general (wound infection and pulmonary
infection) and liver resection associated postoperative mor-
bidity (biliary leakage, post-hepatectomy liver failure and
post-hepatectomy hemorrhage) will be assessed (Table 1).
Type of trial
This is a prospective, randomized, interventional, patient-
blinded single center trial with two parallel comparison
groups.
Randomization
To achieve comparable groups in terms of known and un-
known risk factors, randomization will be performed. The
allocation schedule will be generated by computer-
generated random numbers, with an allocation ratio of 1:1
equal probability of assignment to each group. All patients
will be randomized using consecutively numbered opaque
envelopes sealed by the investigators. Envelopes will be
opened upon entrance of the patient to the operating room.
Blinding
Patients and outcome assessors will be blinded to the
trial intervention. Blinding of the surgeons and people in
the operation is not feasible due to the nature of the
interventions.inutes)
ion (minutes)
(Adobe System Inc., San Jose, CA, USA) computer software, from the
traced onto a paper sheet at the end of liver resection (cm2)
vided by the transection time (cm2/min)
s divided by the transection area (ml/ cm2)
assive hemorrhage (>1,500 ml) during surgery or a hemoglobin level <7 g/dl
(days)
rase, alanine aminotransferase, bilirubin, albumin and international
, three, five and seven
the operation and the reason
d until 90 days after operation. The severity of complications will be
ssification [17].
p of liver surgery (ISGLS) definition (grade A, B or C) [18]
tion (grade A, B or C) [19]
ition (grade A, B or C) [20]
y imaging modality detecting an intra-abdominal fluid collection associated
on of infectious parameters.
ence of increased infection parameters (C-reactive protein >2 mg/dl
by a different pathologic process or evidence of pulmonary infiltration
y.














Selection criteria and informed
consent
×
Medical history demographics ×
Physical examination ×
Laboratory tests × × × × ×
Trial intervention ×
Intraoperative outcomes ×
Postoperative outcomes × × × ×
POD: postoperative days.
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The operations will be performed by one senior surgeon
(XP Geng) who is equally skilled in both the BiClamp for-
ceps and clamp crushing techniques. Except for the trial
interventions, perioperative care will be standardized in
both study groups following the guidelines of the Depart-
ment of General Surgery at the Second Affiliated Hospital
of Anhui Medical University. In addition, all resections will
be performed with the requirement of a low CVP (0 to
5 mm Hg) and an intermittent Pringle maneuver (periods
of 15 minutes of clamping and 5 minutes of unclamping).
Data management and quality assurance
An independent study doctor (JM Chen), who will not
be involved in the treatment and monitoring of the pa-
tients within the operating room, will enter all required
data in the prepared CRF. The CRF should be completed
as soon as possible, preferably at the day of the patient’s
treatment and visit (Table 2). Reasonable explanations
should be given for all missing data. Complete CRF
pages will be checked by the principal investigator and
the responsible monitor with respect to the complete-
ness and plausibility.
Statistical analysis
The two-sided null hypothesis for the primary outcome
measure states that both study interventions lead to
similar total intraoperative blood loss; the alternative hy-
pothesis is that one intervention performs better than
the other. This null hypothesis will be tested by applica-
tion of an analysis of covariance that adjusts for the
transection surface area, CVP, preoperative international
normalized ratio (INR) and preoperative platelet count.
Background characteristics and surgical outcome mea-
sures will be compared using Fisher’s exact tests or chi-
squared for categorical data, and Student’s t-test for
continuous variables. Categorical data will be presented
as frequencies and group percentages, and continuousvariables will be expressed as the means and standard
deviations. The homogeneity of the two groups will be
described by comparing the demographic data and
baseline values. All analyses will be performed on an
ITT basis [16]. For the ITT analysis, data will be proc-
essed for all trial patients in the groups in which they
are randomized. Statistical significance is defined as P
<0.05. All statistical calculations will be performed with
the help of SPSS10.0 (SPSS, Chicago, USA).
Discussion
Since the introduction of the clamp crushing technique
in 1973 [7], this technique has become the gold standard
for liver parenchymal transection due to its effectiveness
in controlling blood loss, reduction in operative time
and low cost. A variety of devices have been developed
to improve parenchymal transection in the past 10 to
15 years [8-10]. However, many randomized studies have
failed to show any significant advantage over the clamp
crushing technique [8-10]. BiClamp forceps, a reusable
bipolar sealing instrument, has been available for open
surgery procedures since 2002 [11]. Our retrospective
data from between July 2007 and July 2014 has shown a
significant reduction in blood loss and lower costs in pa-
tients operated on using BiClamp forceps. Based on
these results, the first randomized controlled trial is de-
signed to evaluate the efficacy, safety and cost-effectiveness
of BiClamp forceps compared to the clamp crushing tech-
nique during elective hepatic resection.
Trial status
The study protocol has been completed in July 2014. En-
rollment started on 1 October 2014. XP Geng performs
approximately 80 hepatectomies per year. The estimated
time frame to randomize 48 patients will be approxi-
mately 20 months.
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